Keywords: transgene, nsclc, vacc, boosts, survival, after, months
Transgene's NSCLC vacc boosts survival after 17 months
Article | 22 September 2008
France's Transgene reported positive clinical results relating to its therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to first-line chemotherapy ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
